	Jun'05	Jun'06	Jun'07	Jun'08	Jun'09	Jun'10	Jun'11	Jun'12	Jun'13	Jun'14	Jun'15	Jun'16	Jun'17	Jun'18	Jun'19	Jun'20	Jun'21	Jun'22	Jun'23	Jun'24
Revenue % growth	425.5 25.4%	607.0 42.7%	716.3 18.0%	835.4 16.6%	920.7 10.2%	1,092.4 18.6%	1,243.1 13.8%	1,368.5 10.1%	1,514.5 10.7%	1,555.0 2.7%	1,678.9 8.0%	1,838.7 9.5%	2,066.7 12.4%	2,340.2 13.2%	2,606.6 11.4%	2,957.0 13.4%	3,196.8 8.1%	3,578.1 11.9%	4,223.0 18.0%	4,685.3 10.9%
Cost of Goods Sold (COGS)	150.6	230.1	331.8	341.6	366.9	436.9	501.8	547.8	573.8	565.2	667.5	772.2	865.0	978.0	1,070.0	1,239.2	1,357.7	1,553.8	1,867.3	2,030.0
Gross Profit % margin	274.9 64.6%	376.9 62.1%	384.5 53.7%	493.8 59.1%	553.8 60.1%	655.5 60.0%	741.3 59.6%	820.7 60.0%	940.7 62.1%	989.8 63.7%	1,011.4 60.2%	1,066.5 58.0%	1,201.7 58.1%	1,362.2 58.2%	1,536.6 59.0%	1,717.8 58.1%	1,839.1 57.5%	2,024.3 56.6%	2,355.7 55.8%	2,655.3 56.7%
Operating Expenses	167.1	244.5	294.3	348.4	360.0	412.1	473.4	525.3	585.8	578.4	596.2	625.2	745.0	801.9	900.6	908.7	926.7	1,024.0	1,203.7	1,335.4
Research & Development Expenses (R&D)	30.0	37.2	50.1	60.5	63.1	75.2	92.0	109.7	120.1	118.2	114.9	118.7	144.5	155.1	180.7	201.9	225.3	253.6	287.6	307.5
Selling, General & Administrative Expenses (SG&A)	135.7	200.2	237.3	278.1	289.9	328.9	371.2	401.6	430.8	450.4	472.6	482.6	554.0	600.4	645.0	676.7	670.4	739.4	874.0	917.1
Operating Income % margin	97.4 22.9%	131.3 21.6%	90.2 12.6%	143.0 17.1%	190.3 20.7%	240.4 22.0%	266.9 21.5%	294.4 21.5%	354.8 23.4%	405.1 26.1%	409.2 24.4%	429.0 23.3%	425.8 20.6%	541.8 23.2%	579.3 22.2%	809.7 27.4%	903.7 28.3%	1,000.3 28.0%	1,131.9 26.8%	1,319.9 28.2%
Interest Income	0.0	0.0	0.0	0.0	0.0	16.7	27.8	33.9	38.9	31.2	26.2	16.9	17.1	16.4	2.3	1.0	0.4	22.3	47.4	0.0
Interest Expense	0.0	1.3	1.3	10.1	10.1	10.1	1.8	4.8	6.4	6.1	5.8	11.2	28.2	28.4	36.2	40.4	24.0	22.3	47.4	45.7
Pre-tax Income	96.6	133.4	98.0	157.9	201.7	260.6	303.7	331.9	385.1	431.1	435.9	439.6	418.7	521.3	518.8	733.1	883.7	960.5	1,101.7	1,264.8
Income Tax % effective tax rate	31.8 33.0%	45.2 33.9%	31.7 32.3%	47.6 30.1%	55.2 27.4%	70.5 27.1%	76.7 25.3%	77.1 23.2%	78.0 20.2%	85.8 19.9%	83.0 19.0%	87.2 19.8%	76.5 18.3%	205.7 39.5%	114.3 22.0%	111.4 15.2%	409.2 46.3%	181.0 18.8%	204.1 18.5%	243.8 19.3%
Net Income % margin	64.8 15.2%	88.2 14.5%	66.3 9.3%	110.3 13.2%	146.4 15.9%	190.1 17.4%	227.0 18.3%	254.9 18.6%	307.1 20.3%	345.3 22.2%	352.9 21.0%	352.4 19.2%	342.3 16.6%	315.6 13.5%	404.6 15.5%	621.7 21.0%	474.5 14.8%	779.4 21.8%	897.6 21.3%	1,021.0 21.8%
EPS	0.47	0.61	0.43	0.72	0.97	1.26	1.49	1.75	2.15	2.44	2.51	2.51	2.42	2.21	2.83	4.31	3.27	5.34	6.12	6.94
Diluted EPS	0.46	0.58	0.43	0.70	0.95	1.23	1.44	1.71	2.10	2.39	2.47	2.49	2.40	2.19	2.80	4.27	3.24	5.30	6.09	6.92
EBITDA % margin	136.9 32.2%	174.0 28.7%	90.2 12.6%	204.8 24.5%	190.3 20.7%	322.2 29.5%	374.3 30.1%	422.6 30.9%	469.8 31.0%	484.9 31.2%	482.3 28.7%	522.7 28.4%	568.9 27.5%	680.2 29.1%	705.8 27.1%	990.4 33.5%	1,099.2 34.4%	1,176.6 32.9%	1,358.8 32.2%	1,533.5 32.7%

Discover more Stock Ideas

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%

S&P Outperformance 19.1%

Next 3M Predicted Return 20.3%

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%

S&P Outperformance 22.3%

Next 3M Predicted Return 26.8%

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%

S&P Outperformance 15.4%

Next 3M Predicted Return 16.9%

More ideas -->

FAQ

1) What is ResMed Inc.'s P/EBIT LTM?

As of today, Microsoft Corp's last 12-month P/EBIT LTM is 23.8x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual P/EBIT LTM for ResMed Inc. have been 30.3x over the past three years, and 33.1x over the past five years.

2) Is ResMed Inc.'s P/EBIT LTM Good?

As of today, ResMed Inc.'s P/EBIT LTM is 23.8x, which is higher than industry median of (0.9x). It indicates that ResMed Inc.'s P/EBIT LTM is Bad.

3) How does ResMed Inc.'s P/EBIT LTM compare to its peers?

As of today, ResMed Inc.'s P/EBIT LTM is 23.8x, which is higher than peer median of 22.1x. The list of peers includes ISRG, ALC, WST, COO, BDX, ATR, HOLX, MASI, BAX, RGEN.

#ResMed Inc. P/EBIT LTM

#ResMed Inc. (RMD) P/EBIT LTM comparison analysis

General

LTM P/EBIT LTM

OTHER METRICS

Company name

Revenue growth

EPS growth

Net Income margin

#RMD key stats

#Discover more Stock Ideas